Medtronic announces the departure of Karen Parkhill, Chief Financial Officer

DUBLIN , June 26, 2024 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in medical technologies, today announced that Karen Parkhill will step down as executive vice president and chief financial officer to assume the role of chief financial officer of HP Inc.

“On behalf of our employees, our executive committee and our board of directors, I want to thank Karen for her leadership over the past eight years. Personally, I am grateful to Karen for her support during my transition to CEO, navigating the pandemic and ensuring a new operating model for the company. We wish her all the best as she begins the next chapter of her career,” said Geoff Martha, president and CEO of Medtronic. “Across the company, we are gaining momentum through our innovation-led growth strategy and remain focused and committed to our short- and long-term financial goals.”

“It has been a pleasure serving Medtronic and our mission over the past eight years,” Parkhill said. “I am grateful to have had the opportunity to lead the outstanding finance team at Medtronic and I know they will continue to deliver on our commitments. I am excited about Medtronic’s plans for the future and, most importantly, the tremendous impact that Medtronic technologies will have on the lives of patients around the world.

The company evaluates candidates for internal and external succession. Parkhill will continue to serve as CFO until her departure on August 2, and Gary Corona, senior vice president of global financial planning and analysis, will serve as interim CFO after her departure.

Additionally, the company also reaffirmed guidance for the first quarter and full fiscal year 2025, as previously disclosed in its earnings and webcast press release dated May 23, 2024.

About Medtronic
Think boldly. Act bolder. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is a leading global medical technology company that boldly attacks the most challenging health challenges facing humanity by seeking and finding solutions. Our mission—to alleviate pain, restore health, and extend life—unifies a global team of more than 95,000 passionate people in more than 150 countries. Our technologies and therapies treat 70 conditions and include heart devices, surgical robotics, insulin pumps, surgical instruments, patient monitoring systems, and more. By drawing on our diverse expertise, insatiable curiosity, and a desire to help those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we deliver insight-driven care, experiences that put people first, and better outcomes for our world. We strive for the extraordinary in everything we do. For more information about Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, production, marketing and sale of medical products, governmental regulation, geopolitical conflicts, general economic conditions and other risks and uncertainties described in the company’s periodic reports on file with the U.S. Securities and Exchange Commission, including the company’s most recent Annual Report on Form 10-K. Medtronic does not undertake any obligation to update its forward-looking statements, including to reflect future events or circumstances.

SOURCE Medtronic plc